Delving into the Latest Updates on Adrenaline with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Adrenaline (JP17), Adrenaline Hydrochlaride, Adrenaline Hydrochloride

+ [58]

Target

adrenergic receptor

Action

agonists

Mechanism

adrenergic receptor agonists(Adrenergic receptors agonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCardiovascular Diseases+ [6]

Active Indication

Intermittent asthmaMydriasisHypersensitivity+ [13]

Inactive Indication-

Originator Organization

Medeca Pharma AB

Active Organization

ALK-Abello A/S

Daiichi Sankyo Co., Ltd.

Nanjing Haiwei Pharmaceutical Technology Co. Ltd.

+ [22]

Inactive Organization

Nxera Pharma Co., Ltd.

Amphastar Pharmaceuticals, Inc.

MannKind Corp.

+ [3]

License Organization

Aptar France SAS

ARS Pharmaceuticals, Inc.Sandoz, Inc.

+ [13]

Drug Highest PhaseApproved

First Approval Date

United States (08 Nov 1967),

Asthma

RegulationPriority Review (United States), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC9H13NO3

InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N

CAS Registry51-43-4

The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and/or drug) or oral immunotherapy (OIT).

Start Date25 Aug 2025

Sponsor / Collaborator

Kokua Pharma Inc

NCT07084753

/ Not yet recruitingNot ApplicableIIT

Comparison of Opioid-based Anesthesia, Opioid-free Anesthesia Based on Intravenous Drugs and Opioid-free Anesthesia With Thoracic Paravertebral Block, in Patients Undergoing Laparoscopic Gastric Bypass Surgery for Obesity

Regional anesthesia is a technique in which a local anesthetic is injected near a nerve or spinal cord to block sensation, motor stimulation, and pain. In this study, an ultrasound-guided paravertebral block will be used, with careful consideration of all positive and negative factors and possible complications. A thoracic paravertebral block is performed by inserting a needle into the intercostal spaces on the back, approximately 4 cm lateral to the spine. Many studies support excellent pain control with this technique, during and after surgery in thoracic and abdominal surgery. Investigators aim to achieve faster patient mobility after surgery, rapid recovery of bowel function, reduced nausea and vomiting, and maximum pain control. The use of opioids, which can additionally cause respiratory suppression and drowsiness, is avoided.
At any time in case of need to switch from laparoscopic to open surgery, equally adequate anesthesia and postoperative analgesia are ensured without the need to change the approach to the same. In this study, the basic scientific assumption (hypothesis) of the researchers is that non-opioid anesthesia with thoracic paravertebral block provides adequate pain control during and long-term after the surgical procedure, without the side effects of opioid anesthesia.
The main goal of the study is to determine which type of anesthesia results in the best pain control and most significantly reduces complications of anesthesia and surgery in overweight patients who are scheduled for laparoscopic longitudinal gastrectomy and partial/total gastrectomy.

Start Date30 Jul 2025

Sponsor / Collaborator

University Hospital Dubrava

100 Clinical Results associated with Adrenaline

Login to view more data

100 Translational Medicine associated with Adrenaline

Login to view more data

100 Patents (Medical) associated with Adrenaline

Login to view more data

46,011

Literatures (Medical) associated with Adrenaline

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Potential anticoagulant mechanism of curdione: Enhancing thrombin inhibition by binding to AT-Ⅲ ‘s D-helix region

Article

Author: Guan, Yuxuan ; Shi, Hanbing ; Zhang, Teng ; Xia, Quan ; Du, Shan ; Wang, Shuhui

ETHNOPHARMACOLOGICAL RELEVANCE:

Curcuma wenyujin was first recorded in the Tang Dynasty's Xinxiu Bencao and has been traditionally used to treat blood stasis syndrome. Its active component curdione exhibits antiplatelet effects, though its anticoagulant mechanisms remain unclear and require further investigation.

AIM OF THE STUDY:

To investigate the anticoagulant activity of curdione, identify potential targets through integrated screening, and elucidate the underlying mechanisms.

MATERIALS AND METHODS:

An acute blood stasis rat model was induced by ice bath stimulation and adrenaline administration. Hemorheological parameters were measured using a hemorheology analyzer, while coagulation function was evaluated using an automated coagulation analyzer. Label-free quantitative proteomics and network pharmacology identified curdione's potential anticoagulant targets. The interaction between curdione and antithrombin Ⅲ (AT-Ⅲ) was confirmed by molecular docking, enzyme-linked immunosorbent assay (ELISA), Western blot analysis, cell thermal shift assay (CETSA), and surface plasmon resonance (SPR) techniques. Site-directed AT-Ⅲ mutagenesis integrated with SPR analysis elucidated the anticoagulant mechanism of curdione.

RESULTS:

Curdione significantly reduced blood and plasma viscosity, prolonged prothrombin time (PT) by approximately 30 %, and inhibited coagulation factors Ⅱ, Ⅶ, Ⅸ, and X, whilst simultaneously enhancing AT-Ⅲ activity in rats with blood stasis. Thrombin and AT-Ⅲ were identified as the key targets, indicating that curdione potentiates AT-Ⅲ-mediated thrombin inhibition via direct binding. Molecular docking and CETSA confirmed their interaction. SPR analysis confirmed curdione binds AT-III's D-Helix (Asn77, Lys157, Arg161, Arg164) with high affinity (4.52E-07 M), potently enhancing thrombin inhibition.

CONCLUSION:

Curdione binds the AT-III D-Helix, enhancing thrombin inhibition and demonstrating potential for treating thromboembolic disorders.

01 Jan 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A UPLC-Q/TOF-MS-based plasma and hippocampal metabolomics analysis was conducted to investigate the impact of Erjing Pills on Alzheimer's Disease rats

Article

Author: Wu, Yi ; Zhu, Na ; Liu, Min ; Zhu, Xu-Dong ; Wu, Qiu-Yun ; Yan, Fei-Xia ; Zhou, Jian ; Yang, Xi-Yang ; Huang, Li-Ping ; Zhang, Peng

Alzheimer's Disease (AD), the most common form of dementia, places a significant burden on individuals and society. In line with the doctrines of Chinese medical practice, kidney deficiency and insufficient marrow cannot nourish the brain, leading to insufficient blood, cerebral dysfunction, and ultimately dementia. Erjing Pills contain wolfberry and Polygonati Rhizoma, which tonify the kidneys and improve the essence. Although pharmacological studies have demonstrated that Erjing Pills can be used to prevent and treat AD, the detailed action mechanism is yet to be determined. To comprehensively reveal the mechanism of action of Erjing Pills in the prevention and treatment of AD, three pharmacodynamic evaluations, the water maze test, both hematoxylin-eosin and immunohistochemical techniques were utilized to assess the effects of Erjing Pills on AD rats. Furthermore, plasma and hippocampus metabolomics were conducted by various statistical analyses combined with UPLC-Q/TOF-MS were employed for a comprehensive and accurate analysis of the in vivo anti-AD effects of Erjing Pills. Erjing Pills enhanced learning and memory capacity decreased hippocampal Aβ deposition expression, and enhanced hippocampal morphology in AD rats. After Erjing Pills treatment, 38 plasma metabolites and 15 hippocampal metabolites of AD rats were regressed to levels similar to those of controls. Moreover, pathways impacted by Erjing Pills on AD included arachidonic acid metabolism, retinol metabolism, glycerophospholipid metabolism, and caffeine metabolism. Additionally, adrenaline, leukotriene B4, retinol, and paraxanthine clearly distinguished the Erjing Pills group from the AD group. These findings significantly enhance our comprehension of the metabolic pathways implicated in AD and shed light on the therapeutic mechanisms of Erjing Pills in alleviating symptoms in rats with AD.

31 Dec 2025·SCANDINAVIAN CARDIOVASCULAR JOURNAL

Ex vivo resuscitation and evaluation of hearts after 22 minutes of normothermic cardiac arrest

Article

Author: Li, Mei ; Steen, Erik ; Steen, Stig ; Pascevivius, Audrius ; Liao, Qiuming

OBJECTIVE:

The aim was to resuscitate and evaluate hearts ex vivo after 22 min of cardiac arrest with the goal of increasing the number of usable hearts from controlled donation after circulatory death (cDCD).

DESIGN:

Eight pigs (39-61 kg) underwent 22 min of ventricular fibrillation, after which the heart was first perfused in vivo for three minutes with an oxygenated, erythrocyte-containing cardioplegic preservation solution. The heart was then explanted and perfused ex vivo with the same solution for three hours at 18 °C in a transportable heart preservation system. Functional evaluation was performed ex vivo (n = 7), while one heart underwent orthotopic transplantation and was monitored for 24 h.

RESULTS:

The seven hearts evaluated ex vivo easily pumped twice the cardiac output measured in vivo. The transplanted heart maintained normal blood pressure, blood gases, and urine output throughout the 24-hour observation period. At the end of this period the aortic pressure was 104/80 mmHg with a heart rate of 129 beats per minute. Intravenous administration of 20, 40, and 100 µg adrenaline resulted in an aortic pressures of 238/171, 284/196, and 287/201 mmHg with corresponding heart rates of 162, 188, and 223 beats per minute.

CONCLUSION:

Hearts exposed to 22 min of cardiac arrest were successfully resuscitated ex vivo and demonstrated adequate function when evaluated.

382

News (Medical) associated with Adrenaline

19 Nov 2025

·www.globenewswire.com

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector Dosing of the first participant in the Phase 2 study in Canada reflects the successful initiation of the Company’s needle-free epinephrine delivery program for anaphylaxis treatment Interim results are expected in the first quarter of 2026 Nov. 18, 2025 - Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the successful initiation of the Company's Phase 2 clinical study with dosing of the first participant in Canada. The trial aims to evaluate NS002, the Company's investigational intranasal epinephrine powder formulation, compared to EpiPen for the treatment of anaphylaxis. NS002 could potentially offer patients a needle-free alternative to traditional epinephrine autoinjectors. The Phase 2 study is an open-label, fixed-sequence trial designed to evaluate the pharmacokinetic parameters and hemodynamic responses of NS002 compared to EpiPen in 50 healthy adults with a history of allergic rhinitis. Interim results from this trial are expected in the first quarter of 2026. “The dosing of the first participant in our Phase 2 study marks a significant milestone for our NS002 program and for patients with severe allergies who need more user-friendly treatment options to manage life-threatening anaphylaxis,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “We are moving forward at full speed, executing the NS002 development program as planned, and positioning the Company for its next stage of growth. For millions suffering from severe allergies, the fear of needles and the inconvenience of carrying cumbersome autoinjectors leads to poor compliance and potentially life-threatening outcomes in anaphylaxis management.” Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

14 Nov 2025

·www.einpresswire.com

Nove Device Expands Access to Lifesaving Naloxone Nasal Spray Carry Case

Nove Device creates discreet, everyday-carry kits to hold emergency naloxone nasal sprays, empowering users to respond quickly and without stigma. SAN FRANCISCO, CA, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Nove Device continues to redefine public health preparedness with its innovative single dose nasal spray carry case for life saving medications such as Narcan ® (naloxone HCl), Kloxxado ® (naloxone HCl), Tosymra ® (sumatriptan), Imitrex ® (sumatriptan), Neffy ® (epinephrine nasal spray), or Zavzpret ® (zavegepant). The company is dedicated to providing people and organizations with life-saving equipment in times of need. Safety and Accessibility The company builds its naloxone nasal spray carry cases with safety and reliability in mind. Designed for first responders, healthcare professionals, and individuals in mind, the product gives quick and discreet storage of naloxone, ensuring it’s always within reach when seconds matter most. Combining innovation with compassion, the company provides durable, user-friendly designs that suit both active lifestyles and professional use. Their commitment to advancing life-saving technologies is evident through their continuous product enhancements and dedication to quality. Innovating Life-Saving Solutions Naloxone nasal spray carry solutions instill confidence in communities by promoting readiness, safety, and peace of mind. Each device reflects its passion for emergency response accessibility. Trusted by Leading Organizations Trusted by leading organizations, Nove Device is a reliable source that supplies durable, user-friendly emergency kits to communities through naloxone distribution and public health programs. Collaborations with healthcare providers, prevention programs, and first responders help to make naloxone keychain kits more accessible, empowering communities to respond swiftly in times of crisis. Leading health organizations across the U.S. trust Nove Device's "Emergency Nasal Spray Carry Case + Keychain" for its reliability and quick-access design. About Nove Device: Nove Device creates discreet, everyday-carry kits to hold emergency naloxone nasal sprays, empowering users to respond quickly and without stigma. For more information or to explore their full range of innovative products, contact their office or visit their website. Company name: Nove Device Address: 1917 Ellis Street Unit 3 State: California City: San Francisco Zip Code: 94115 Phone number: +1 317-445-3130 Email Address: contact@novedevice.com Nove Device Nove Device +1 317-445-3130 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

14 Nov 2025

·www.einpresswire.com

Nove Device Introduces Innovative Naloxone Nasal Spray Carry Case for Emergency Preparedness

This kit is designed to educate individuals and communities on recognizing and responding to an overdose effectively. SAN FRANCISCO, CA, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Nove Device has announced the launch of its innovative naloxone nasal spray carry case for emergency use. Committed to improving public safety and accessibility, the company continues to develop smart, reliable solutions designed to make life-saving tools more accessible during critical moments. Design for Saving Life The naloxone nasal spray carry emergency case is built with durability, portability, and discretion in mind. It ensures that users can keep their life saving medication, secure, and within easy reach at all times, including Narcan ® (naloxone HCl), Kloxxado ® (naloxone HCl), Tosymra ® (sumatriptan), Imitrex ® (sumatriptan), Neffy ® (epinephrine nasal spray), or Zavzpret ® (zavegepant. Designed for first responders, healthcare professionals, and everyday individuals, this carry case allows users to respond effectively in overdose and other life threatening emergencies. They specialize in practical design, and public health distribution, reflecting their ongoing commitment to community safety and innovation. Expanding Safety Solutions Beyond its functional advantages, the naloxone nasal spray carry case stands out for its modern, compact design that supports an active lifestyle. They prioritize quality materials, convenience, and protective features that offer peace of mind when every second counts. The company continues to expand its product line to meet the growing demand for health and safety products, enabling the public to be prepared wherever they go. Educational and Practical Design This kit is designed to educate individuals and communities on recognizing and responding to an overdose effectively. Each kit includes clear, easy-to-follow information and tools needed to act quickly—ideal for naloxone distribution programs or personal preparedness. About Nove Device: Nove Device designs innovative, portable naloxone carry cases that enhance emergency preparedness, promote overdose awareness, and empower communities to save lives safely and effectively. For more information or to learn more about their life-saving innovations, contact their office or visit their website. Company name: Nove Device Address: 1917 Ellis Street Unit 3 State: California City: San Francisco Zip Code: 94115 Phone number: +1 317-445-3130 Email address: contact@novedevice.com Nove Device Nove Device +1 317-445-3130 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Adrenaline

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00095	Adrenaline	C01CA24 B02BC09 S01EA01	DB00668

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Intermittent asthma	United States	Armstrong Pharmaceuticals, Inc.	07 Nov 2018
Mydriasis	United States	Ph Healthcare Services	07 Dec 2012
Hypersensitivity	United States	Viatris Specialty LLC	22 Dec 1987
Anesthesia	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Bronchial Spasm	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hemorrhage	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hypotension	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Shock	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Anaphylaxis	China	Grand Pharmaceutical Group	01 Jan 1981
Heart Arrest	China	Grand Pharmaceutical Group	01 Jan 1981
Asthma	United States	Wyeth Consumer Healthcare LLC	08 Nov 1967

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rhinitis, Allergic	Phase 2	Canada	Nasus Pharma Ltd.	03 Nov 2025
Rhinitis, Allergic, Seasonal	Phase 2	Canada	Nasus Pharma Ltd.	03 Nov 2025
Persistent asthma	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Urticaria	Phase 2	United States	ARS Pharmaceuticals Operations, Inc.	28 Jul 2022
Hypersensitivity, Immediate	Phase 2	Canada	Aquestive Therapeutics, Inc.	12 Jul 2022
Drug Hypersensitivity	Phase 1	Sweden	Orexo AB	22 Apr 2024
Respiratory Tract Infections	Phase 1	Australia	ARS Pharmaceuticals, Inc.	09 Aug 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02722746 (Pilot epinephrine dose-finding study, CTgov)	Phase 1/2	Analgesia \| Hypotension	66	Ropivacaine (Ropivacaine Only Control Group)	ykvoxioujp: percent difference = 20.8 (95% CI, -8.9 to 47.3), P-Value = 0.165	-	18 Jun 2025
				Ropivacaine+Epinephrine (Ropivacaine + 2 mcg/mL Epinephrine)
GlobeNewswire Manual	Not Applicable	Oral allergy syndrome	-	Anaphylm (with allergen exposure)	zrlzzptcxr(ohtorlwtwu) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. kwdzpxeljl (cmypelxvup ) Met View more	Positive	24 Oct 2024
				Anaphylm (without allergen exposure)
NCT04207840 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	Phase 4	Asthma \| Anaphylaxis	28	Epinephrine MDI	wadzksgxdp(vymmedmhoo) = vrlxaskmke hndxwapuvt (llbqxsagbj )	Positive	29 Aug 2024
				Epinephrine IM	wadzksgxdp(vymmedmhoo) = hcuzpahvjs hndxwapuvt (llbqxsagbj )
NCT03126968 (PROPHET, CTgov)	Phase 2/3	Hemorrhage \| Lung transplant rejection \| Hemoptysis	66	Topical epinephrine (Prophylactic Topical Epinephrine)	zvoatkykjd = ipmlmzoqic mslvrbwjyl (svzmqzkynk, qynltfiagy - zvacukrayt) View more	-	28 Aug 2024
				Placebos (Placebo)	zvoatkykjd = rqmlngdkjd mslvrbwjyl (svzmqzkynk, dpuzzmztni - secgvysvib) View more
GlobeNewswire Manual	Not Applicable	Hypersensitivity	36	Anaphylm™ (epinephrine) Sublingual Film	llvjkhowck(aunzuczwhd) = afyudfaqoc mdussxrjvg (clfztcooxc ) Met	Positive	25 Jul 2024
				Adrenalin manual intramuscular (IM) injection	llvjkhowck(aunzuczwhd) = chxctynmjm mdussxrjvg (clfztcooxc ) Met
NCT05881915 (MD-245-2022, Pubmed)	Not Applicable	Hypotension	98	Epinephrine infusion (0.03 mcg/kg/min)	ihtlrhizlr(lkrdgyaiyk) = deggvxfggk uklwbamrpy (kkocbbiehd )	Positive	25 May 2024
				Phenylephrine infusion (0.4 mcg/kg/min)	ihtlrhizlr(lkrdgyaiyk) = dbexdhghtn uklwbamrpy (kkocbbiehd )
GlobeNewswire Manual	Phase 3	Hypersensitivity	100	Anaphylm (single dosing part)	zvpppnhaxb(icfmnhyblj) = gkokwaymmf wzkqjjgcvr (ktfingqlsl ) View more	Positive	14 Mar 2024
				Anaphylm (repeat dosing part)	farlrfcval(acgefsuisa) = rxowrzfohj oyzkimpepy (xrsdfmvtuu ) View more
JPRN-jRCT2031230143 (AAAAI 12024 \| AAAAI 22024) Manual	Phase 3	Hypersensitivity \| Anaphylaxis	15	neffy 1.0mg	xtiheyewoz(madykuvvmr) = dirxicpaho yvkvqfmqdi (oleyuxkdrb ) View more	Positive	24 Feb 2024
				neffy 2.0mg	xtiheyewoz(madykuvvmr) = uhsaitbjya yvkvqfmqdi (oleyuxkdrb ) View more
AAAAI2024	Not Applicable	-	-	Epinephrine Nasal Spray 13.2 mg	pyybkbavto(gmlkelmpyb) = biasdlxgac anvcpfnxir (kwkudsaras, 107) View more	-	23 Feb 2024
NCT05496465 (AAAAI2024)	Phase 2	Urticaria	-	肾上腺素鼻喷雾剂-ARS-1	uhspvrehts(dcwiiydkdm) = kvkrqevjro ytbjxgoxhy (jdumkpfyiv )	Positive	23 Feb 2024
				安慰剂	-